Targeted therapy depends on targeting unique receptors or proteins in the malignant cells, thus leading to fewer chemotherapy-induced adverse effects. Subhajit Hazra and Sara Ahmed Zaki demonstrate how to achieve the highest benefit from the targeted therapy, to focus on developing the diagnostic tools to identify the highest priority targets in each patient.